Dermatologic adverse events of checkpoint inhibitors: What an oncologist should know

Immunotherapy

Volumn 8, Issue 12, 2016, Pages 1437-1446

  Habre, Maya ^a   Habre, Samer Bassilios ^b   Kourie, Hampig R ^c  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

autoimmunity; cancer immunology; checkpoint inhibitors; immune related adverse events; immunotherapy; skin manifestations

Indexed keywords

ANTIHISTAMINIC AGENT; ATEZOLIZUMAB; BEVACIZUMAB; CHECKPOINT KINASE INHIBITOR; CORTICOSTEROID; IPILIMUMAB; LIDOCAINE; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; T LYMPHOCYTE RECEPTOR;

ACNEIFORM RASH; ADRENAL INSUFFICIENCY; ALOPECIA; CANCER COMBINATION CHEMOTHERAPY; COLITIS; CRYOTHERAPY; CUTANEOUS ALLERGIC ANGEITIS; DERMATOMYOSITIS; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRESS SYNDROME; DRUG MECHANISM; DYSPNEA; FATIGUE; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; KIDNEY CARCINOMA; LICHENOID EXANTHEMA; LOW LEVEL LASER THERAPY; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; PAPULAR ERYTHEMATOUS LESION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PRURIGO; PRURITUS; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT DISEASE; REVIEW; SARCOIDOSIS; SKIN DEFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW (TOPIC); TOXIC EPIDERMAL NECROLYSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; VASCULITIS; VOMITING; XEROSTOMIA; ADVERSE EFFECTS; ALGORITHM; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXANTHEMA; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; VITILIGO;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXANTHEMA; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRURITUS; VITILIGO;

EID: 85007199223     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0074     Document Type: Review

References (47)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015).
3. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627-1639 (2015).
4. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015).
5. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803-1813 (2015).
6. Hoffman-Censits JH, Grivas P, Van Der Heijden MS et al. IMvigor 2, a Phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J. Clin. Oncol. 34(Suppl. 2S), Abstract 355 (2016).
7. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
8. Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521-2532 (2015).
9. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of highrisk stage III melanoma (EORTC 18071): a randomised, double-blind, Phase III trial. Lancet Oncol. 16(5), 522-530 (2015).
10. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23-34 (2015).
11. Kourie H, Klastersky J. Immune checkpoint inhibitors: side effect and management. Immunotherapy, under review. Immunotherapy 8(7), 799-807 (2016).
12. Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J. Am. Acad. Dermatol. 71(1), 161-169 (2014).
13. Ibrahim RA, Berman DM, de Pril V et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol. 29(Suppl.), Abstract 8583 (2011).
14. Wolchok J, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with previously treated, advanced melanoma: a randomized, double-blind, multicenter, Phase II, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
15. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, Phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer. Res. 15, 5591-5598 (2009).
16. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm, Phase II study. Ann. Oncol. 21, 1712-1717 (2010).
17. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and metaanalysis. BMC Med. 13, 211 (2015).
18. Attia P, Phan GQ, Maker AJ et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 25, 6043-6053 (2005).
19. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of skin rash associated with ipilimumab in patients with cancer: a systematic review of literature and metaanalysis. J. Am. Acad. Dermatol. 69, e121-e128 (2013).
20. Jaber SH, Cowen EW, Haworth LR et al. Skin reactions in a subset of patients with stage IV melanoma treated with anticytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142, 166-172 (2006).
21. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 23, 498-501 (2013).
22. Rudolph BM, Staib F, Von Stebut E, Hainz M, Grabbe S, Loquai C. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma-simultaneous occurrence of pyoderma gangrenosum and colitis. Eur. J. Dermatol. 24(2), 268-269 (2014).
23. Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced Grover disease. Br. J. Dermatol. 171(5), 1236-1237 (2014).
24. Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8(1), e53745 (2013).
25. Nordlund JJ, Kirkwood JM, Forget BM et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol. 9, 689-696 (1983).
26. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218(1), 69-70 (2009).
27. Reule RB, North JP. Cutaneous and pulmonary sarcoidosislike reaction associated with ipilimumab. J. Am. Acad. Dermatol. 69(5), e272-e273 (2013).
28. Sheik Ali S, Goddard AL, Luke JJ et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 151(2), 195-199 (2015).
29. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann. Intern. Med. 84(1), 68-76 (1976).
30. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med. 326, 363 (1992)
31. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study. J. Invest. Dermatol. 128, 35-44 (2008).
32. Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol. 16, 1-2 (2015).
33. Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 151(7), 797-799 (2015).
34. Joseph RW, Cappel M, Goedjen B et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol. Res. 3(1), 18-22 (2015).
35. La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 35(10), 963-976 (2015).
36. Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 151(11), 1206-1212 (2015).
37. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
38. Ascierto PA, Marincola FM, Atkins MB. What's new in melanoma? Combination. J. Transl. Med. 13, 213 (2015).
39. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006-2017 (2015).
40. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am. Soc. Clin. Oncol. Educ. Book 2015, 76-83 (2015).
41. Puzanov I, Callahan M, Linette G et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J. Clinical. Oncol. 32(15), 2511 (2014).
42. Hodi FS, Lawrence D, Lezcano C et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer. Immunol. Res. 2, 632-642 (2014)
43. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J. Am. Acad. Dermatol. 72(2), 221-236; quiz 237-238 (2015).
44. Yervoy (ipilimumab) US prescribing information: risk evaluation and mitigation strategy. Bristol-Myers Squibb Company, Princeton, NJ (2011). http://packageinserts.bms. com/pi/pi-yervoy.pdf
45. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann. Transl. Med. 4(14), 272 (2016).
46. Riley P, McCabe MG, Glenny A. Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment. JAMA Oncol. 2(10), 1365-1366 (2016).
47. Hua C, Boussemart L, Mateus C et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 152(1), 45-51 (2016).